pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
406
stories
8d
STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care
stat
8d
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
biospace
8d
Oura to acquire AI virtual primary care partner Counsel Health for $625M
fiercebiotech
8d
STAT+: GLP-1s are given an FDA warning for rare eye condition risk
stat
8d
STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
stat
8d
STAT+: PepGen says early trial for muscular dystrophy drug looks promising
stat
9d
BioSpace 2027 Best Places to Work shines light on most admired employers
biospace
9d
STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke
stat
9d
FDA orders GLP-1 drugmakers to warn of rare eye disease
endpoints
9d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
9d
STAT+: Heart association meeting’s readout is trending ‘neutral’
stat
9d
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
stat
9d
AI chatbots aren’t therapists. But can they finally get men to open up?
stat
10d
MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
fda medwatch
10d
Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...
raps
12d
Two incoming lawmakers plan to defend health equity from Trump administration cuts
stat
12d
Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing
biospace
12d
Most people haven’t heard of kratom. What is it, and who’s using it?
stat
13d
FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
fda press
13d
Preeclampsia almost took her life and her baby's. Drugs are finally underway
endpoints
13d
RevMed’s Rasonque shatters analyst estimates with $198M quarter
biospace
13d
STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
stat
14d
Cloudbreak posts phase 3 eye disease win amid IPO storm
fiercebiotech
14d
Spyre’s arthritis misses; Ideaya ends eye cancer trial
endpoints
14d
Top health takeaways from the midterm elections
stat
14d
Opinion: I moved to Europe for free health care. I miss my patient portal
stat
14d
Minghui grants ASKA Japanese rights to sub-q TED candidate in $440M deal
fiercebiotech
14d
nPhase rakes in $30M to expand AI-native clinical data platform
fiercebiotech
14d
China biotech Minghui does thyroid eye disease deal for $110M upfront
endpoints
15d
How a Ms. Frizzle-esque librarian helped Flagship’s Louisa Helms find biotech
biospace
← prev
page 2 of 14
next →